Topic

Venture Capital

21
Jul
2015

How Are Biotech VCs Performing in the Boom? You’d Be Surprised (Part 2)

Yesterday, I published the first half of a two-part series on biotech venture fund performance in the boom. That story included data from venture funds backed by public employees in three states–Pennsylvania, California, and Hawaii. Today, I’m following up with more disclosures from funds in Washington and North Carolina, plus the big California fund that invests retirement savings for schoolteachers.
11
May
2015

How Do VCs Divvy Up Their Pay?

Venture capitalists are notorious for keeping their performance a secret. But an even bigger mystery is who has the power inside firms, and how that gets reflected in their pay. Compensation is a sign of who’s who inside a firm, and what it values. It’s frequently the thing that tears apart firms in both bad times and good. While much...
Read More
23
Feb
2015

Who Is Poised To Go Public in 2015, and Who Isn’t?

This is the greatest bull market ever for biotech IPOs, which everyone reading this surely knows. If Dr. Seuss were around, he’d ask something like: “How long can it go? Nobody knows.” Renaissance Capital counted 102 healthcare IPOs last year, more than one-third of all the new stock offerings in the U.S. An infusion of more than $9 billion flowed to...
Read More
17
Feb
2015

Frazier, Versant Find an AFib Drug To Bet on at Laguna

Before becoming a venture capitalist, Jamie Topper was a cardiologist. He hasn’t had many chances over the past decade to invest in the field he knows best. Only the deepest pockets of Big Pharma could develop successful new heart drugs. But this time, Topper sees things differently at a little company called Laguna Pharmaceuticals.
12
Feb
2015

Video: Alnylam’s John Maraganore and Canaan’s Julie Papanek at BIO CEO

Biotech is undoubtedly one of the most volatile businesses on the planet. John Maraganore of Alnylam knows that well. The CEO of Alnylam Pharmaceuticals has been there for the whole classic biotech roller coaster ride. Back in the early 2000s, scientists were electrified by the possibilities to treat the untreatable with RNA interference drug technology. Then, pharma companies ran for...
Read More